/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
SASKATOON, SK, April 10, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management provides an update on its previously announced non-brokered private placement (the "Offering"). As disclosed in the Company's news release dated March 20, 2026, ZYUS raised a total of CAD$284,300 in gross proceeds in the first tranche of the Offering, which closed on March 20, 2026. The Company confirms that no additional tranches were completed, no additional proceeds were received, and no further securities will be issued under the Offering. The Company continues to evaluate additional financing opportunities as needed. The Company has drawn down on its revolving credit facility to meet its working capital requirements.
Read more at newswire.ca